Pacira BioSciences, Inc.

PCRX Healthcare Drug Manufacturers Specialty & Generic

Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.24%, EPS grew 209.1%, free cash flow grew 502.5% and total debt fell 37.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

36.35 0.02 +0.06%
Market cap
$1.5B
P/E
104×
Fwd P/E
33.7×
Dividend yield
—
F-score
8/9
Altman Z
2.02
Beneish M
−2.93
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

2.90% 0.96% 0.71% 2.05%
Piotroski F-Score
8 8 8 8
ROA
1.52% 0.50% 0.37% 1.05%
ROIC
3.03% 1.45% 1.84% 1.58%
Return on Tangible Assets
3.55% 1.24% 0.95% 2.35%
Average Days of Receivables
58.70 62.34 62.40 64.78
Free Cash Flow per Share
2.82 3.07 3.28 4.55
Free Cash Flow
124.20 136.66 132.71 179.52
Other line items

Show all line items

Columns are period end dates